SCHEMBL19377576

SCHEMBL19377576

Nc1ncnn2c1c(-c1ccc(NC(=O)c3cccn(-c4ccccc4)c3=O)cc1)cc2[C@H]1CC[C@@H](O)CC1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
▸ TYRO3 Q06418 15/20 1.00
▸ AXL P30530 9/20 1.00
▸ MERTK Q12866 6/20 0.86

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19377751 1.00 TYRO3 (1.00) TYRO3AXLMERTK
SCHEMBL19377578 1.00 TYRO3 (1.00) TYRO3AXLMERTK
SCHEMBL19377746 0.93 TYRO3 (1.00) TYRO3AXLMERTK
SCHEMBL19377848 0.93 TYRO3 (1.00) TYRO3AXLMERTK
SCHEMBL19377621 0.93 TYRO3 (1.00) TYRO3AXLMERTK
SCHEMBL23370630 0.93 TYRO3 (0.87) TYRO3AXLMERTK
SCHEMBL21923067 0.93 TYRO3 (0.87) TYRO3AXLMERTK
SCHEMBL19429601 0.93 TYRO3 (0.87) TYRO3AXLMERTK
SCHEMBL19377849 0.93 AXL (1.00) TYRO3AXLMERTK
SCHEMBL26613618 0.93 TYRO3 (0.89) TYRO3AXLMERTK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-114456175-B Pyrrolotriazine compounds as TAM inhibitors 因赛特公司 2024-09-03 — — CN claimed
EP-3436461-B1 PYRROLOTRIAZINE COMPOUNDS AS TAM INHIBITORS INCYTE CORP (US) 2023-11-01 — — EP claimed
US-20170275290-A1 PYRROLOTRIAZINE COMPOUNDS AS TAM INHIBITORS INCYTE CORPORATION 2017-09-28 — — US claimed
US-20260042765-A1 PYRROLOTRIAZINE COMPOUNDS AS TAM INHIBITORS INCYTE CORP (US) 2026-02-12 — — US disclosed
US-12415809-B2 Pyrrolotriazine compounds as tam inhibitors INCYTE CORPORATION (US) 2025-09-16 — — US disclosed
CN-114456175-B Pyrrolotriazine compounds as TAM inhibitors 因赛特公司 2024-09-03 — — CN disclosed
CN-114456176-B Pyrrolotriazine compounds as TAM inhibitors 因赛特公司 2024-08-30 — — CN disclosed
US-20240124463-A1 PYRROLOTRIAZINE COMPOUNDS AS TAM INHIBITORS INCYTE CORPORATION 2024-04-18 — — US disclosed
EP-4321513-A2 PYRROLOTRIAZINE COMPOUNDS AS TAM INHIBITORS Incyte Corporation (US) 2024-02-14 — — EP disclosed
EP-3436461-B1 PYRROLOTRIAZINE COMPOUNDS AS TAM INHIBITORS INCYTE CORP (US) 2023-11-01 — — EP disclosed
US-11591338-B2 Pyrrolotriazine compounds as TAM inhibitors INCYTE CORPORATION (US) 2023-02-28 — — US disclosed
US-10442810-B2 Pyrrolotriazine compounds as TAM inhibitors INCYTE CORPORATION (US) 2019-10-15 — — US disclosed
US-10442810-B2 Pyrrolotriazine compounds as TAM inhibitors INCYTE CORPORATION (US) 2019-10-15 — — US disclosed
US-20180327412-A1 PYRROLOTRIAZINE COMPOUNDS AS TAM INHIBITORS INCYTE CORPORATION 2018-11-15 — — US disclosed
US-9981975-B2 Pyrrolotriazine compounds as tam inhibitors INCYTE CORPORATION (US) 2018-05-29 — — US disclosed
US-9981975-B2 Pyrrolotriazine compounds as tam inhibitors INCYTE CORPORATION (US) 2018-05-29 — — US disclosed
US-9981975-B2 Pyrrolotriazine compounds as tam inhibitors INCYTE CORPORATION (US) 2018-05-29 — — US disclosed
US-20170275290-A1 PYRROLOTRIAZINE COMPOUNDS AS TAM INHIBITORS INCYTE CORPORATION 2017-09-28 — — US disclosed
US-20170275290-A1 PYRROLOTRIAZINE COMPOUNDS AS TAM INHIBITORS INCYTE CORPORATION 2017-09-28 — — US disclosed
US-20170275290-A1 PYRROLOTRIAZINE COMPOUNDS AS TAM INHIBITORS INCYTE CORPORATION 2017-09-28 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260042765-A1 PYRROLOTRIAZINE COMPOUNDS AS TAM INHIBITORS MAP2K2, TTK, MAP2K5 TYRO3 96/4885AXL 107/4885MERTK 16/4885
US-20180327412-A1 PYRROLOTRIAZINE COMPOUNDS AS TAM INHIBITORS MERTK, MAP3K15, MAP3K5 TYRO3 106/4885AXL 49/4885MERTK 1/4885
US-20170275290-A1 PYRROLOTRIAZINE COMPOUNDS AS TAM INHIBITORS MERTK, MAP3K15, MAP3K5 TYRO3 106/4885AXL 49/4885MERTK 1/4885
US-10442810-B2 Pyrrolotriazine compounds as TAM inhibitors MERTK, MAP3K15, MAP3K5 TYRO3 106/4885AXL 49/4885MERTK 1/4885
US-12415809-B2 Pyrrolotriazine compounds as tam inhibitors MERTK, MAP3K15, MAP3K5 TYRO3 106/4885AXL 49/4885MERTK 1/4885
US-11591338-B2 Pyrrolotriazine compounds as TAM inhibitors MERTK, MAP3K15, MAP3K5 TYRO3 106/4885AXL 49/4885MERTK 1/4885
US-20240124463-A1 PYRROLOTRIAZINE COMPOUNDS AS TAM INHIBITORS MERTK, MAP3K15, MAP3K5 TYRO3 106/4885AXL 49/4885MERTK 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback